Last updated: February 17, 2026
What Is the Status and Market Position of Drug NDC 00115-1487?
NDC 00115-1487 corresponds to Balversa (erdafitinib), marketed by Janssen Pharmaceuticals. It is an oral tyrosine kinase inhibitor approved in 2019 for locally advanced or metastatic bladder cancer with FGFR3 or FGFR2 genetic alterations. This drug addresses a niche market within oncology, specifically targeted therapies for bladder cancer.
Market Dynamics and Competitive Landscape
Balversa entered a market with limited direct competitors. Key competitors include other FGFR inhibitors such as:
- Erdafitinib (Balversa/Janssen) – FDA-approved for FGFR-mutated bladder cancer
- Infigratinib (BGJ398) – Investigated for similar indications
- Futibatinib (Tefino) – An FGFR inhibitor with potential competitive positioning
Other systemic therapies for advanced bladder cancer outside FGFR targeting include chemotherapy agents and immunotherapies such as pembrolizumab and atezolizumab.
Market Size and Sales Data
In its first full year (2020), Balversa generated approximately $107 million in U.S. sales (IQVIA data). Growth projections depend on approval expansions, ongoing clinical trials, and market penetration.
Regulatory and Clinical Development Influences
The Drug's expansion relies on:
- Additional approvals for broader indications
- Clinical trial results for combination therapies
- Broader biomarker testing adoption among bladder cancer patients
Pricing and Reimbursement Landscape
Current Pricing Strategies
Balversa's wholesale acquisition cost (WAC) is approximately $19,500 per month for a typical treatment course.
| Pricing Metric |
Estimated Cost |
| Monthly WAC |
$19,500 |
| Annualized (12 months) |
$234,000 |
This high price is consistent with targeted oncology therapies with limited patient populations. Reimbursement is primarily facilitated through Medicare, Medicaid, and commercial insurers, with coverage dependent on biomarker testing confirming FGFR alterations.
Cost-Effectiveness and Value Assessment
Health technology assessment (HTA) agencies evaluate cost-effectiveness based on:
- Survival benefits
- Quality-adjusted life years (QALYs)
- Comparative efficacy with other therapies
Limited real-world evidence suggests moderate improvements in progression-free survival, but the high cost limits widespread adoption outside specialized centers.
Future Price Projections and Market Trends
Factors Influencing Price Trajectory
- Broader FDA approvals could expand patient access, possibly reducing per-patient costs via economies of scale.
- Competition with emerging FGFR inhibitors may pressure prices downward.
- Bulk purchasing agreements and value-based pricing models might influence future pricing.
Forecasting Scenarios
- Short-term (1-2 years): Slight price stability, with potential discounts for expanded indications.
- Mid-term (3-5 years): Prices could decline 10-20% if additional FGFR inhibitors gain approval and market share increases.
- Long-term: Entry of biosimilars or generic versions is unlikely given molecule complexity and patent protections.
Regulatory and Patent Considerations
- Johnson & Johnson holds multiple patents protecting Balversa's formulation and use.
- Patent expirations are not expected before 2030, limiting generic competition in the near term.
- Additional indications pending regulatory review could extend exclusivity periods.
Summary
Balversa is a niche targeted therapy with steady but limited market growth, priced at around $19,500/month. Sales remain confined to specialized settings. Price evolution will depend on clinical success, competition, and reimbursement policies, with minor downward pressure expected over the next five years.
Key Takeaways
- Balversa (erdafitinib) is a targeted FGFR inhibitor approved for limited bladder cancer indications.
- U.S. sales reached approximately $107 million in 2020; growth depends on expanded indications and market penetration.
- Current pricing is roughly $19,500 per month, with limited short-term price reduction prospects.
- Competition from other FGFR inhibitors and biosimilars could influence future pricing.
- Patent protections extend potentially well into the 2030s, maintaining market exclusivity.
FAQs
1. What factors most influence the pricing of erdafitinib?
Pricing is influenced by clinical efficacy, market exclusivity, manufacturing costs, competition, and reimbursement negotiations.
2. Will erdafitinib's price decrease if more FGFR inhibitors enter the market?
Yes. Increased competition often leads to price reductions, especially if multiple drugs target the same genetic alterations.
3. How does biomarker testing impact erdafitinib's marketability?
Biomarker testing for FGFR mutations is essential for patient selection; widespread testing can increase eligible patient pools, influencing sales.
4. Are there ongoing clinical trials that could alter erdafitinib’s market presence?
Yes; trials investigating combination regimens and broader indications may improve its positioning and justify price adjustments.
5. What are the main challenges to lowering erdafitinib's price?
Patent protections, high R&D costs, limited market size, and the need to recoup investments sustain high prices.
References
[1] IQVIA. "2020 Oncology Market Data."
[2] FDA. "FDA approves Erdafitinib for bladder cancer." (2019)
[3] Johnson & Johnson. "Balversa (erdafitinib) prescribing information."
[4] Evaluate Pharma. "Forecasts for targeted oncology drugs."
